Prasong TanmahasamutRatikorn SaejongManee RattanachaiyanontSurasak AngsuwathanaKitirat TechatraisakNutchaya Sanga-AreekulMahidol University2018-12-212019-03-142018-12-212019-03-142017-07-03Gynecological Endocrinology. Vol.33, No.7 (2017), 534-53914730766095135902-s2.0-85014520733https://repository.li.mahidol.ac.th/handle/20.500.14594/41845© 2017 Informa UK Limited, trading as Taylor & Francis Group. Objective: To determine the effectiveness of desogestrel for relieving endometriosis-related pain. Methods: A double-blinded randomized placebo-controlled trial was conducted in 40 patients who had endometriosis with moderate-to-severe dysmenorrhea or chronic pelvic pain undergoing laparoscopic conservative surgery. After surgery, patients were randomized to desogestrel or placebo group. Outcomes included changes in visual analog scale (VAS) of dysmenorrhea, pelvic pain and dyspareunia, patient satisfaction, and adverse effects. Results: Forty patients were randomized to desogestrel group (n = 20) and placebo group (n = 20). At month 6, the desogestrel group had significantly lower median VAS of overall pelvic pain, dysmenorrhea and noncyclic pelvic pain. Comparing with the placebo group, the desogestrel group had greater reduction in VAS of overall pain, dysmenorrhea and pelvic pain, but comparable reduction in VAS of dyspareunia. No patient in the desogestrel group but 4 patients in the placebo group still had moderate-to-severe pelvic pain at 6 months postoperatively. The proportion of patients who rated the treatment as very satisfied was higher in the desogestrel group than in the placebo group. There was no serious adverse event during the study period. Conclusions: Desogestrel is effective and acceptable for postoperative therapy for patients with moderate-to-severe pain related to endometriosis.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1080/09513590.2017.1296124